Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun(Edinburgh Cancer Research), John Fuller(The Royal Free Hospital), Valentine Charlton-Menys(Manchester Royal Infirmary), G. A. Hitman, Margaret J. Thomason(University College London), Paul N. Durrington(University of Manchester), H. A. W. Neil(University of Ulster), D. J. Betteridge, Michael I. Mackness(Manchester Royal Infirmary), Shona Livingstone(University College London)
The Lancet
August 1, 2004
10.1016/s0140-6736(04)16895-5
Cited by 3,790

Related Papers

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Vascular Risk Factors and Diabetic Neuropathy
|New England Journal of Medicine|2005|1.3k
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
|JAMA|2012|800
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785